Modification of the Reactivity of Guinea-Pig Seminal Vesicles to Angiotensin and Tyramine by some Microsomal Enzyme Inducers

  • A. L. Gascon
  • J. Brodeur
  • M. G. Côté
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 8)


Previous reports have shown that neither angiotensin nor tyramine can stimulate the isolated guinea-pig seminal vesicles (Gascon and Walaszek, 1968; Gascon and Vaillancourt, 1969). However, both compounds are seen to induce a contraction of this isolated smooth muscle when they are applied after the addition of adrenaline. This effect is completely antagonized by phenoxybenzamine and a rapid tachyphylaxis develops, indicating an action via the release of endogenous catecholamine from extra-neuronal sites of storage. In another series of experiments, there was a marked increase in the reactivity of the isolated seminal vesicles to angiotensin and tyramine following pretreatment of guinea-pigs with testosterone and nandrolone (Gascon et al., 1969). Prior to 1956, the anabolic properties of androgens were thought to be restricted to secondary sexual tissues. During the past decade or so, data have been accumulating to indicate that the anabolic properties of androgens could also extend to non-sexual tissues. Axelrod, 1956, Quinn et al., 1958, Murphy and DuBois, 1958 and Booth and Gillette, 1962, among others have shown that various androgens exert potent anabolic effects upon drug metabolizing enzymes located in the microsomal fraction of mammalian liver.


Seminal Vesicle Stimulant Effect Mammalian Liver Endogenous Catecholamine Pretreated Animal 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. J. AXELROD. J. Pharmacol. Exp. Therap. 117, 322 (1956)Google Scholar
  2. J. BOOTH and J.R. GILLETTE. J. Pharmacol. Exp. Therap. 137, 374 (1962)Google Scholar
  3. A.H. CONNEY. Pharmacol. Rev. 19, 317 (1967)PubMedGoogle Scholar
  4. A.H. CONNEY, I.A. MICHAELSON and J.J. BURNS. J. Pharmacol. Exp. Therap. 132, 202 (1961)Google Scholar
  5. A.L. GASCON, J. BRODEUR and M. VAILLANCOURT. J. Pharm. Pharmacol. 21, 325 (1969)PubMedCrossRefGoogle Scholar
  6. A.L. GASCON and M. VAILLANCOURT. Arch. Inter. Pharmacodyn. Therap. (in press)Google Scholar
  7. A.L. GASCON and E.J. WALASZEK. Arch. Inter. Pharmacodyn. Therap. 175, 265 (1968)Google Scholar
  8. R. KATO and E. CHIESARA. Brit. J. Pharmacol. 18, 29 (1962)PubMedGoogle Scholar
  9. W. LEVIN, R.M. WELCH and A.H. CONNEY. Steroids 13, 155 (1969)PubMedCrossRefGoogle Scholar
  10. R.A. MUELLER and F.E. SHIDEMAN. Biochem. Pharmacol. 17, 451 (1968)PubMedCrossRefGoogle Scholar
  11. S.D. MURPHY and K.P. DUBOIS. J. Pharmacol, Exp. Therap. 124, 194 (1958)Google Scholar
  12. D. PALM, C. ERNZERHOFF und P. HOLTZ. Arch. Pharmak. u. exp. Path. 258, 352 (1967)Google Scholar
  13. Z.P. PICARELLI and J.R. VALLE. Brit. J. Pharmacol. 35, 468 (1969)Google Scholar
  14. G.P. QUINN, J. AXELROD and B.B. BRODIE. Biochem. Pharmacol. 1, 152 (1958)CrossRefGoogle Scholar

Copyright information

© Plenum Press, New York 1970

Authors and Affiliations

  • A. L. Gascon
  • J. Brodeur
  • M. G. Côté
    • 1
  1. 1.Department of Pharmacology, Faculty of MedicineUniversity of MontrealMontrealCanada

Personalised recommendations